10.01.2019, 1632 Zeichen
Agrana: The first three quarters of the 2018|19 financial year of Agrana, the manufacturer of fruit products, sugar and starch, were defined by very low sales prices in the Sugar and Starch segments. Revenues declined by 7.1 % to Euro 1.863,5 mn, EBIT by 63 % to Euro 63.5 mn and the profit for the period by 71 % to Euro 37.0 mn. Chief Executive Officer Johann Marihart comments: “The persistent depressed prices for sugar and isoglucose after the end of the EU quotas, as well as ethanol prices significantly lower than one year earlier, are sharply impacting this year’s earnings. Revenue in the Fruit segment is stable, with the fruit juice concentrate business generating satisfactory EBIT earnings thanks to better contribution margins from apple juice concentrate from the 2017 harvest.”
Agrana: weekly performance:
Amag: Austrian aluminium group Amag reported preliminary figures for 2018. With total shipments of approx. 424,600 tonnes (2017: 421,700 tonnes), revenue increased to approx. Euro 1.1 bn (2017: Euro 1.0 bn). The preliminary EBITDA of the Amag Group in the 2018 financial year of approx. Euro 141 mn (2017: Euro 164.5 mn) is below the earnings guidance published on October 31, 2018. This is mainly caused by unfavourable valuation effects in Q4/2018, especially in connection with the decrease in the aluminium and alumina price at the end of 2018. Furthermore, earnings are influenced by slightly deviations in shipments and start-up costs for the site expansion, the company stated.
Amag: weekly performance:
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (10/01/2019)
Wiener Börse Party #1145: ATX dank Andritz mit Hydropower fester, Raiffeisen Research passt den Game Plan an
Aktien auf dem Radar:AT&S, UBM, Strabag, Polytec Group, Lenzing, EuroTeleSites AG, Uniqa, ATX, ATX Prime, ATX TR, Wolford, ATX NTR, RBI, OMV, Mayr-Melnhof, Telekom Austria, Palfinger, Andritz, Marinomed Biotech, Österreichische Post, voestalpine, BKS Bank Stamm, Oberbank AG Stamm, Amag, CA Immo, EVN, CPI Europe AG, Kapsch TrafficCom, Semperit, RHI Magnesita.
Marinomed
Marinomed hat die Vision, das Leben von Patienten, die an Krankheiten mit unzureichenden Behandlungsmöglichkeiten leiden, in zwei wichtigen therapeutischen Bereichen nachhaltig zu verbessern: Virologie und Immunologie.
>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner
Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab.
Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.
Newsletter abonnieren
Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)
per Newsletter erhalten